Next-generation aldosterone synthase inhibitors

About Mineralys Therapeutics

Mineralys Therapeutics is pioneering a new approach to treating hypertension by targeting aldosterone synthase, a key enzyme in the renin-angiotensin-aldosterone system. The company's lead candidate, lorundrostat, has demonstrated promising results in Phase 2 trials for patients with uncontrolled hypertension, showing significant blood pressure reductions. With a management team experienced in cardiovascular drug development and a clear focus on addressing a major unmet medical need, Mineralys is positioned to advance its clinical programs toward potential regulatory approval. The company's strategy centers on developing targeted therapies that address the root causes of hypertension rather than just managing symptoms.

Therapeutic Areas

Other Hypertension Drugs